146 related articles for article (PubMed ID: 17628778)
1. [Research at the Ulm University in prostate cancer].
Rinnab L; Cronauer M; Spindler D; Hautmann RE; Küfer R
Urologe A; 2007 Sep; 46(9):1071-7. PubMed ID: 17628778
[No Abstract] [Full Text] [Related]
2. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
[TBL] [Abstract][Full Text] [Related]
3. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data.
Rouzier C; Haudebourg J; Carpentier X; Valério L; Amiel J; Michiels JF; Pedeutour F
Cancer Genet Cytogenet; 2008 May; 183(1):21-7. PubMed ID: 18474293
[TBL] [Abstract][Full Text] [Related]
4. Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development.
Attard G; Ang JE; Olmos D; de Bono JS
J Clin Pathol; 2008 Aug; 61(8):891-6. PubMed ID: 18495790
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetics of prostate cancer: clinical translational opportunities.
Vecchione A; Gottardo F; Gomella LG; Wildemore B; Fassan Ms; Bragantini E; Pagano F; Baffa R
J Exp Clin Cancer Res; 2007 Mar; 26(1):25-37. PubMed ID: 17550130
[TBL] [Abstract][Full Text] [Related]
6. Genomic gestalt.
Kiser K
Minn Med; 2005 Apr; 88(4):11-2. PubMed ID: 15940884
[No Abstract] [Full Text] [Related]
7. [Molecular biology of prostate carcinoma].
Urologe A; 1997 May; 36(3 Suppl Molekular):1-8. PubMed ID: 9304276
[No Abstract] [Full Text] [Related]
8. Autochthonous mouse models for prostate cancer: past, present and future.
Huss WJ; Maddison LA; Greenberg NM
Semin Cancer Biol; 2001 Jun; 11(3):245-60. PubMed ID: 11407949
[TBL] [Abstract][Full Text] [Related]
9. ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer.
Turner DP; Watson DK
Expert Rev Anticancer Ther; 2008 Jan; 8(1):33-42. PubMed ID: 18095881
[TBL] [Abstract][Full Text] [Related]
10. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
[TBL] [Abstract][Full Text] [Related]
11. [Detection and significance of fusion gene between TMPRSS2 and ETS transcription factor genes in fresh prostatic cancer tissues in Chinese patients].
XIANG H; LING ZX; SUN K; REN GP; YOU QH; ZHU XZ
Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):187-8. PubMed ID: 21575391
[No Abstract] [Full Text] [Related]
12. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
Shah RB; Chinnaiyan AM
Adv Anat Pathol; 2009 May; 16(3):145-53. PubMed ID: 19395877
[TBL] [Abstract][Full Text] [Related]
13. [Dangerous liaisons in prostate cancer. Clinical and biological implications of recurrent gene fusions].
Perner S
Pathologe; 2010 Oct; 31 Suppl 2():121-5. PubMed ID: 20798944
[TBL] [Abstract][Full Text] [Related]
14. Risk loci, biological candidates and biomarkers.
Nat Genet; 2008 Mar; 40(3):257. PubMed ID: 18305468
[No Abstract] [Full Text] [Related]
15. Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11.
Thomadaki H; Mavridis K; Talieri M; Scorilas A
Thromb Haemost; 2009 Feb; 101(2):373-80. PubMed ID: 19190824
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronan-mediated motility: a target in oral squamous cell carcinoma.
Yamano Y; Uzawa K; Shinozuka K; Fushimi K; Ishigami T; Nomura H; Ogawara K; Shiiba M; Yokoe H; Tanzawa H
Int J Oncol; 2008 May; 32(5):1001-9. PubMed ID: 18425326
[TBL] [Abstract][Full Text] [Related]
17. [Frequent gene fusion in prostate cancer: clinical applications in diagnosis, prognosis and therapy].
Schmidt F; Scheble V; Mertz K; Perner S; Rubin MA
Dtsch Med Wochenschr; 2009 Jul; 134(28-29):1483-6. PubMed ID: 19572250
[TBL] [Abstract][Full Text] [Related]
18. Beyond PSA: utility of novel tumor markers in the setting of elevated PSA.
Lin DW
Urol Oncol; 2009; 27(3):315-21. PubMed ID: 19414121
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
[TBL] [Abstract][Full Text] [Related]
20. Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions.
Teixeira MR
Am J Surg Pathol; 2008 Apr; 32(4):642-4; author reply 644. PubMed ID: 18317354
[No Abstract] [Full Text] [Related]
[Next] [New Search]
